Detailed Narrative
Q4 FY26 Performance Overview and FY27 Outlook
FY26 was a transitional year for Piramal Pharma, marked by macroeconomic headwinds, subdued biopharma funding in H1, and inventory de-stocking, leading to a year-on-year decline in reported revenues and EBITDA. However, when adjusted for de-stocking, the underlying business showed modest growth. The company exited the year on a stronger note, anticipating a return to healthy early-to-mid-teen revenue growth in FY27, with EBITDA and PAT growing faster. Revenue is expected to be H2 weighted in FY27, with growth momentum building progressively from Q2 onwards.
CDMO Business Dynamics and Growth Drivers
The CDMO segment reported revenues of INR 1,708 crores in Q4 FY26 and INR 4,915 crores for the full year. While H1 was impacted by slower RFPs, H2 saw a significant rebound in biopharma funding, leading to accelerated RFP activity and order inflows, particularly for overseas sites with superior gross margins. The company's win rate increased last year, attributed to its asset combination, strengthened business development, and high customer satisfaction, reflected in a Net Promoter Score of 60. Innovation-related work contributed 47% of FY26 CDMO revenues, with 96 million USD from on-patent commercial manufacturing.
Strategic Investments and Capacity Expansion
Piramal Pharma is investing $90 million to expand sterile injectables and payload linker capabilities at its Lexington and Riverview sites. The Riverview expansion is already completed, while the larger Lexington phase is progressing as planned and is targeting completion by the end of calendar year 2027. These investments, alongside an expanded CDMO commercial team, aim to capitalize on high demand for differentiated capabilities like ADCs and HPAPI, and to leverage the onshoring trend, which is seen as a significant tailwind.
Complex Hospital Generics (CHG) and Consumer Healthcare (CHC) Performance
The CHG business strengthened its US market leadership in inhalation anesthesia, with market share increasing to 47% by March 2024. The acquisition of Kenalog from BMS was completed and is expected to contribute revenue from Q2 FY27, bolstering the differentiated products portfolio. The CHC business demonstrated strong and consistent growth, with 17% revenue growth in Q4 FY26 and for the full year. This growth was driven by Power Brands, which grew 24% for the full year, and the e-commerce channel, which saw 48% growth and now accounts for approximately 30% of total PCH sales.
Capital Allocation, Debt Management, and Intangible Write-down
The company reported a net debt-to-EBITDA ratio of 3.6 at the end of FY26, which is expected to remain in a similar range for FY27 due to ongoing capex. The FY27 capex is projected to be INR 120-135 million, primarily for the Lexington expansion. A one-time📎 intangible asset write-down of INR 176 crores was recorded in Q4 FY26. This impairment resulted from a strategic decision to cut further investments in certain development projects where market conditions changed and financial outcomes did not meet return ratios.
Regulatory Compliance and ESG Initiatives
Piramal Pharma maintained a strong quality and regulatory track record, successfully completing 38 regulatory inspections, including three US FDA inspections, without any official action indicated (OAI). The company also underwent 209 customer audits during the year, reflecting heightened customer engagement. Sustainability efforts led to improved ESG ratings, with a score of 68.5 from SES ESG Research and 64 from NSE Sustainability Ratings, demonstrating commitment to decarbonization, waste management, and supply chain practices.